The European Medicines Agency has recommended the refusal of the marketing authorisation for Turalio, a medicine intended for the treatment of tenosynovial giant cell tumour from Plexxicon/Daiichi Sankyo.
Daiichi Sankyo Company, Limited announced that the FDA approved Turalto (pexidartinib) as the first and only treatment for adult patients...